Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marla Chapman

Pediatrics Hattiesburg, MS Medical Doctor

NPI 1114331832 CMS profile 765281

4210 Lincoln Rd, Hattiesburg, MS 39402

Open in the dashboard

General payments

$2,345

123 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marla Chapman of Hattiesburg, MS is reported in the CMS Open Payments database as having received $2,345 across 123 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $344 13
2024 General $300 16
2023 General $462 26
2022 General $432 23
2021 General $387 18
2020 General $102 7
2019 General $317 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marla Chapman
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Marla Chapman were reported at $344. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Marla Chapman Pediatrics median Middle half National median
2019 $317 $86 $31–$183 $163
2020 $102 $49 $22–$110 $114
2021 $387 $68 $27–$158 $132
2022 $432 $77 $30–$173 $149
2023 $462 $88 $33–$190 $160
2024 $300 $94 $34–$206 $164
2025 $344 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $296 19 payments
  2. Corium, Inc. $269 15 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $224 12 payments
  4. GlaxoSmithKline, LLC. $203 13 payments
  5. Tris Pharma Inc $200 12 payments
  6. Merck Sharp & Dohme Corporation $165 10 payments
  7. Ironshore Pharmaceuticals Inc. $159 10 payments
  8. Dexcom, Inc. $135 1 payment
  9. Sanofi Pasteur Inc. $116 7 payments
  10. Baxter Healthcare $109 2 payments
  11. Other $468 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,178 120 payments
  2. Debt forgiveness $167 3 payments
Products named General payments · program years 2019–2025
  1. Azstarys $269 15 payments
  2. VYVANSE $255 15 payments
  3. BEXSERO $203 13 payments
  4. TRUMENBA $185 12 payments
  5. GARDASIL 9 $165 10 payments
  6. PEDIARIX $144 10 payments
  7. VAXNEUVANCE $139 8 payments
  8. VAXELIS $139 8 payments
  9. Dexcom G6 Transmitter $135 1 payment
  10. SYNAGIS $109 6 payments
  11. Other $1,537 89 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record